-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
HC Wainwright Reiterates "Buy" Rating for First Wave BioPharma (NASDAQ:FWBI)
HC Wainwright Reiterates "Buy" Rating for First Wave BioPharma (NASDAQ:FWBI)
First Wave BioPharma (NASDAQ:FWBI – Get Rating)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 231.49% from the stock's current price.
First Wave BioPharma Stock Performance
FWBI stock opened at $5.43 on Thursday. The business has a 50 day moving average price of $1.40 and a 200 day moving average price of $2.98. First Wave BioPharma has a fifty-two week low of $3.01 and a fifty-two week high of $348.60.
Get First Wave BioPharma alerts:First Wave BioPharma (NASDAQ:FWBI – Get Rating) last posted its earnings results on Monday, November 14th. The company reported $2.60 earnings per share for the quarter, topping the consensus estimate of ($3.01) by $5.61. Analysts forecast that First Wave BioPharma will post -43.53 EPS for the current fiscal year.
Institutional Investors Weigh In On First Wave BioPharma
An institutional investor recently raised its position in First Wave BioPharma stock. State Street Corp boosted its position in shares of First Wave BioPharma, Inc. (NASDAQ:FWBI – Get Rating) by 97.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,593 shares of the company's stock after buying an additional 40,755 shares during the period. State Street Corp owned 6.02% of First Wave BioPharma worth $122,000 as of its most recent SEC filing. Institutional investors own 1.98% of the company's stock.First Wave BioPharma Company Profile
(Get Rating)
First Wave BioPharma, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Featured Articles
- Get a free copy of the StockNews.com research report on First Wave BioPharma (FWBI)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for First Wave BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Wave BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
First Wave BioPharma (NASDAQ:FWBI – Get Rating)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 231.49% from the stock's current price.
第一波生物製藥 (納斯達克:FWBI — 獲得評分)賓辛加（Beninga）報導，在周四向客戶和投資者發布的一份研究報告中，HC Wainwright 的研究分析師重申了其「買入」評級。他們目前的股票目標價格為 18.00 美元。溫賴特的價格目標將表明該股票的價格目標可能比股票當前價格上漲 231.49％。
First Wave BioPharma Stock Performance
第一波生物製藥股票表現
FWBI stock opened at $5.43 on Thursday. The business has a 50 day moving average price of $1.40 and a 200 day moving average price of $2.98. First Wave BioPharma has a fifty-two week low of $3.01 and a fifty-two week high of $348.60.
五銀國際股票周四開盤價 5.43 美元。該業務的 50 天移動平均價格為 1.40 美元，200 日移動平均價格為 2.98 美元。第一波生物製藥有五十二周低點 3.01 美元，五十二周高點為 348.60 美元。
First Wave BioPharma (NASDAQ:FWBI – Get Rating) last posted its earnings results on Monday, November 14th. The company reported $2.60 earnings per share for the quarter, topping the consensus estimate of ($3.01) by $5.61. Analysts forecast that First Wave BioPharma will post -43.53 EPS for the current fiscal year.
第一波生物製藥 (NASDAQ: FWBI — 獲取評級) 上次公佈其盈利業績週一, 11 月 14 日.該公司報告了本季度每股盈利 2.60 美元，超過了 5.61 美元的共識估計（3.01 美元）。分析師預測，第一波生物製藥將在本會計年度錄得 -43.53 每股盈利。
Institutional Investors Weigh In On First Wave BioPharma
機構投資者權衡第一波生物製藥
First Wave BioPharma Company Profile
第一波生物製藥公司簡介
(Get Rating)
(取得評分)
First Wave BioPharma, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
First Wave BioPharma, Inc. 是一家臨床階段生物製藥公司，致力於治療胃腸道疾病患者的標靶性和非系統性療法的研究和開發。它的候選產品包括硝氯胺，一種具有抗病毒和抗炎特性的口服小分子；以及生物產學 adrulipase（一種重組脂肪酶），旨在消化脂肪和其他營養物質。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on First Wave BioPharma (FWBI)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取第一波生物製藥研究報告
- 市場節拍週的回顧 — 1/23-1/27
- 為什麼清醒在一天內飆升近 100％
- 乘坐這些鐵路股票以獲得增長和收入
- ASML 今年看到籌碼需求上升，提高了銷售觀點
- KLA 公司：陷入困境的半市場中的實力
Receive News & Ratings for First Wave BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Wave BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收第一波生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關第一波生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧